Literature DB >> 36268386

Facial spasms revealing a Parry-Romberg syndrome: A case report.

Ahmadou Bamba Mbodji1, Momar Seck1, Ngor Side Diagne1, Ibrahima Faye1, Serigne Saliou Mbacke1, Moustapha Ndiaye1.   

Abstract

Introduction and importance: Parry-Romberg syndrome (PRS) is a rare clinical entity characterized by progressive atrophy of the hemifacial region, occasionally associated with systemic manifestations. The presence of facial muscles spasms is exceptional. Case presentation: We report the case of a young woman who presented with progressive atrophy of the right hemiface associated with vitiligo and facial muscles spasms. The diagnosis of Parry Romberg syndrome was retained. Electromyogram showed an intermittent motor unit potential. Cerebral MRI showed atrophy of the muscle and subcutaneous fat of the right hemiface. She received corticosteroid in combination with botulinum toxin injection, which stopped the spasms. Clinical discussion: It is a rare condition with a poorly understood etiology, which is responsible for the delay in diagnosis often noted. The association of this syndrome with neurological signs is exceptional and rarely described in the literature. Injection of botulinum toxin associated with corticosteroids can stop the spasms but only surgery can reduce the facial deformities.
Conclusion: Parry-Romberg syndrome is a rare disease, more frequent in women. It poses a real diagnostic problem and its treatment is poorly codified.
© 2022 The Authors.

Entities:  

Keywords:  Botulinum toxin; Facial muscles spasms; Hemifacial atrophy; Parry-Romberg syndrome

Year:  2022        PMID: 36268386      PMCID: PMC9577821          DOI: 10.1016/j.amsu.2022.104716

Source DB:  PubMed          Journal:  Ann Med Surg (Lond)        ISSN: 2049-0801


  11 in total

Review 1.  Successful treatment of Parry-Romberg syndrome with autologous fat grafting: 14-year follow-up and review.

Authors:  Joseph P Hunstad; David A Shifrin; Bill G Kortesis
Journal:  Ann Plast Surg       Date:  2011-10       Impact factor: 1.539

2.  Pallidal lesions. Structural and functional magnetic resonance imaging.

Authors:  S F Bucher; K C Seelos; R C Dodel; W Paulus; M Reiser; W H Oertel
Journal:  Arch Neurol       Date:  1996-07

3.  The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines.

Authors:  Riaz A Agha; Thomas Franchi; Catrin Sohrabi; Ginimol Mathew; Ahmed Kerwan
Journal:  Int J Surg       Date:  2020-11-09       Impact factor: 6.071

4.  Classification and treatment of facial tissue atrophy in Parry-Romberg disease.

Authors:  José Guerrerosantos; Fernando Guerrerosantos; Jessica Orozco
Journal:  Aesthetic Plast Surg       Date:  2007 Sep-Oct       Impact factor: 2.326

Review 5.  Progressive hemifacial atrophy: a review.

Authors:  Stanislav N Tolkachjov; Nirav G Patel; Megha M Tollefson
Journal:  Orphanet J Rare Dis       Date:  2015-04-01       Impact factor: 4.123

6.  Neurological Manifestations in Parry-Romberg Syndrome: 2 Case Reports.

Authors:  Justine Vix; Stéphane Mathis; Mathieu Lacoste; Rémy Guillevin; Jean-Philippe Neau
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

7.  Treatment of hemifacial spasm in patient with hemifacial atrophy using combination therapy (ultrasound therapy and TENS): a case report.

Authors:  Apala Baduni; Bhuvana Krishnamoorthy
Journal:  Korean J Pain       Date:  2017-09-29

8.  [Chronic corneal ulcer revealing Parry-Romberg's syndrome: a case report].

Authors:  Sara El Maroufi; Ahmed Bennis; Fouad Chraibi; Meriem Abdellaoui; Idriss Benatiya Andaloussi
Journal:  Pan Afr Med J       Date:  2021-01-18

9.  Coexistence of Parry-Romberg syndrome with homolateral segmental vitiligo.

Authors:  Marta Janowska; Katarzyna Podolec; Sylwia Lipko-Godlewska; Anna Wojas-Pelc
Journal:  Postepy Dermatol Alergol       Date:  2013-12-18       Impact factor: 1.837

10.  Parry-Romberg syndrome. Physical, clinical, and imaging features.

Authors:  Hasan Aydın; Zeynel Yologlu; Husamettin Sargın; Melike Rusen Metin
Journal:  Neurosciences (Riyadh)       Date:  2015-10       Impact factor: 0.735

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.